Overall, although further studies are needed, our data suggest that the SIRT7/JNK-Akt-lipogenesis axis could be considered as a potential target pathway for developing novel anti-remodeling therapy for PAH. This evidence concerns the gene AKT1 and pulmonary arterial hypertension.